Cargando…
Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies
BACKGROUND: The ability to discriminate indolent from clinically significant prostate cancer (PC) at the initial biopsy remains a challenge. The ExoDx Prostate (IntelliScore) (EPI) test is a noninvasive liquid biopsy that quantifies three RNA targets in urine exosomes. The EPI test stratifies patien...
Autores principales: | Margolis, Erik, Brown, Gordon, Partin, Alan, Carter, Ballentine, McKiernan, James, Tutrone, Ronald, Torkler, Phillipp, Fischer, Christian, Tadigotla, Vasisht, Noerholm, Mikkel, Donovan, Michael J., Skog, Johan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9184274/ https://www.ncbi.nlm.nih.gov/pubmed/34593984 http://dx.doi.org/10.1038/s41391-021-00456-8 |
Ejemplares similares
-
Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL
por: Tutrone, Ronald, et al.
Publicado: (2020) -
Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome
por: Kretschmer, Alexander, et al.
Publicado: (2022) -
ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis
por: Tutrone, Ronald, et al.
Publicado: (2023) -
A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy
por: McKiernan, James, et al.
Publicado: (2020) -
Validation of a CE-IVD, urine exosomal RNA expression assay for risk assessment of prostate cancer prior to biopsy
por: Kretschmer, Alexander, et al.
Publicado: (2022)